These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30951201)

  • 1. Proceedings of a Workshop: US Food and Drug Administration-International Society of Pharmacometrics Model-Informed Drug Development in Oncology.
    Bruno R; Jin JY; Maxfield K; Milligan L; Liu C; Wang Y; McKee AE; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):81-83. PubMed ID: 30951201
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-World Data for Pediatric Pharmacometrics: Can We Upcycle Clinical Data for Research Use?
    Van Driest SL; Choi L
    Clin Pharmacol Ther; 2019 Jul; 106(1):84-86. PubMed ID: 30942897
    [No Abstract]   [Full Text] [Related]  

  • 3. The US Food and Drug Administration's Model-Informed Drug Development Paired Meeting Pilot Program: Early Experience and Impact.
    Madabushi R; Benjamin JM; Grewal R; Pacanowski MA; Strauss DG; Wang Y; Zhu H; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):74-78. PubMed ID: 31081932
    [No Abstract]   [Full Text] [Related]  

  • 4. A Call for Objective Dose Selection to Increase Success in Pediatric Clinical Trials: A Perspective From NICHD and NIMH Program Staff.
    Giacoia G; Grabb MC; Pawlyk AC; Ren Z; Samedy-Bates L; Taylor-Zapata P
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S9-S12. PubMed ID: 34185908
    [No Abstract]   [Full Text] [Related]  

  • 5. Model-Informed Drug Development: A Regulatory Perspective on Progress.
    Zhu H; Huang SM; Madabushi R; Strauss DG; Wang Y; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):91-93. PubMed ID: 31162631
    [No Abstract]   [Full Text] [Related]  

  • 6. Identifying potential prescription drug product hopping.
    Gowda V; Beall RF; Kesselheim AS; Sarpatwari A
    Nat Biotechnol; 2021 Apr; 39(4):414-417. PubMed ID: 33846649
    [No Abstract]   [Full Text] [Related]  

  • 7. [Under FDA scrutiny: 19 drugs monitored for safety concerns].
    Sabourin G
    Perspect Infirm; 2010; 7(2):44-5. PubMed ID: 21744604
    [No Abstract]   [Full Text] [Related]  

  • 8. Growth of REMS challenges FDA, stakeholders.
    Traynor K
    Am J Health Syst Pharm; 2010 Aug; 67(15):1221-2. PubMed ID: 20651308
    [No Abstract]   [Full Text] [Related]  

  • 9. The FDA's poor oversight of postmarketing studies.
    Lancet; 2009 Nov; 374(9701):1568. PubMed ID: 19897111
    [No Abstract]   [Full Text] [Related]  

  • 10. An overview of drug development in the United States and current challenges.
    Moore SW
    South Med J; 2003 Dec; 96(12):1244-55; quiz 1256. PubMed ID: 14696877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pivotal Role of Translation in Anti-Infective Development.
    Friberg LE
    Clin Pharmacol Ther; 2021 Apr; 109(4):856-866. PubMed ID: 33523464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Data, Advanced Analytics, and the Evolution of Postmarket Drug Safety Surveillance.
    Dal Pan GJ
    Clin Pharmacol Ther; 2019 Jul; 106(1):28-30. PubMed ID: 30958565
    [No Abstract]   [Full Text] [Related]  

  • 13. Progress in Drug Development-Pediatric Dose Selection: Workshop Summary.
    Wang J; van den Anker JN; Burckart GJ
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S13-S21. PubMed ID: 34185909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing prescription drug innovation and adoption.
    Alexander GC; O'Connor AB; Stafford RS
    Ann Intern Med; 2011 Jun; 154(12):833-7, W-301. PubMed ID: 21690598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020.
    Green FG; Park K; Burckart GJ
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S28-S35. PubMed ID: 34185898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.
    Faucette S; Wagh S; Trivedi A; Venkatakrishnan K; Gupta N
    Clin Transl Sci; 2018 Mar; 11(2):123-146. PubMed ID: 29266809
    [No Abstract]   [Full Text] [Related]  

  • 17. New Drugs Approved in 2019.
    Ebied AM; Patel KH; Cooper-DeHoff RM
    Am J Med; 2020 Jun; 133(6):675-678. PubMed ID: 32145207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FDA's patient-focused drug development initiative.
    Kluetz PG; Bhatnagar V
    Clin Adv Hematol Oncol; 2021 Feb; 19(2):70-72. PubMed ID: 33596186
    [No Abstract]   [Full Text] [Related]  

  • 19. Post-marketing surveillance of prescription drug safety: past, present, and future.
    Chen BK; Yang YT
    J Leg Med; 2013; 34(2):193-213. PubMed ID: 23980746
    [No Abstract]   [Full Text] [Related]  

  • 20. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.